CHMP backs Novo's insulin products

EMA's CHMP issued several positive opinions Friday, including recommending approval of two insulin products from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) to treat Type I and II diabetes: Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart. The products are under review in the U.S., with a meeting of FDA's Endocrinologic and Metabolic Drugs Advisory Committee scheduled for Nov. 8 to discuss the applications. Insulin degludec is a long-acting insulin analog, while insulin degludec/insulin aspart is a combination of 70% insulin Degludec and 30% Novo Nordisk's NovoLog insulin aspart. ...